anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PROBLEM TO BE SOLVED: To obtain a composite pigment having an excellent discoloration- preventing effect, a high dispersing property, a light weight, a smooth touch and a high UV light-shielding effect by applying a specific amount of silica on the surfaces of titanium dioxide particles. SOLUTION: This composite pigment is obtained by applying 15-50 wt.% of silica on the surfaces of titanium dioxide particles. The titanium dioxide particles constituting the pigment preferably have an average particle diameter of 0.01-0.2 μm. When the amount of the silica applied on the titanium dioxide particles is <15 wt.%, the discoloration-preventing effect of the titanium dioxide is low, and the high dispersing property and the smooth touch are not obtained. When the amount of the silica applied on the titanium dioxide particles is >50 wt.%, the UV light-shielding effect is deteriorated, and the objective effect is not obtained. The composite pigment can by processed in the form of a liquid cosmetic, a cream-like cosmetic, an oily solid cosmetic, a pressed solid-like cosmetic, a powdery cosmetic, etc.  Although arbitrarily selected in response to the kind of the cosmetic, the amount of the pigment to be added to the cosmetic is preferably 0.5-95 wt.% based on the cosmetic, more preferably 1-50 wt.%.
L-Bcl-2 Antisense oligonucleotide (BP1002) is given in a sequential, dose escalation design. Starting dose is 20mg/m\^2.
This was an open-label, rising single-dose study to investigate the pharmacokinetics of the investigational agent, MP-3180, and to evaluate the use of the Optical Renal Function Monitor (ORFM), an investigational noninvasive fluorescence detection device. Single-dose pharmacokinetics at four dose levels were evaluated following the administration of a single, intravenous dose of MP-3180. Iohexol was also administered followed by saline. Prior to administration of MP-3180 and iohexol, ORFM sensor probes were affixed to four locations on the body of each participant. The noninvasive fluorescent signal from MP-3180 was measured using the ORFM investigational device continuously for approximately four hours post MP-3180 administration. For the determination of the pharmacokinetic disposition of MP-3180 and iohexol, blood samples were collected from each participant provided the individual completed all blood collections in the study. The pharmacokinetics of MP-3180 and iohexol were assessed by statistical comparison of pharmacokinetic parameters derived from plasma concentration-time curves and urine recovery data.
Adverse events related to drug therapy are a major cause of iatrogenicity. They are responsible of increased morbidity, leading to hospitalization, sometimes in emergency, and mortality, not only in ambulatory care but also during hospitalization itself. Causes are multiple : among them, confusion leading to an erroneous drug administration, mistakes regarding dosage, risks associated to self-medication, drug-drug interactions or even food-drug interactions. Elderly population is exposed to an increased incidence of drug iatrogenicity because older patients cumulate numerous risk factors, especially polypharmacy and cognitive disorders. Prevention of drug iatrogenicity is a key objective from a public health point of view. Preventive measures should target the prescriber (physician), the dispenser (pharmacist), the user (patient) and the supplier (pharmaceutical industry).
The present invention relates to a monoclonal antibody which can be specially combined with an open reading frame (ORF) 2 (a sequence is disclosed in SEQ ID NO: 1) of hepatitis E virus (HEV), or a conservative variant of the monoclonal antibody or an active fragment, or other monoclonal antibodies which have cross reactivity with the monoclonal antibody in the present invention and aims at ORF2, and encoding nucleotide sequences or degeneracy sequences of the monoclonal antibodies. The present invention also discloses an antigenic determinant on hepatitis E virus ORF 2 and a method for sieving separated or recombined polypeptide or polypeptide analogs, and the polypeptide or the polypeptide analogs has or have the characteristic which is equivalent to that of an antigenic determinant 1) or 3) of the hepatitis E virus ORF2 and is combined with the monoclonal antibody 8C11 and 8H3 of the present invention. The present invention also discloses polypeptide or polypeptide analogs obtained by sieving via the method, and encoding nucleotide sequences or degeneracy sequences of the polypeptide, discloses the application of the polypeptide or the polypeptide analogs for preparing medicines for diagnosing and/or preventing hepatitis E virus infection and additionally discloses a kit used for diagnosing hepatitis E virus infection and vaccine used for preventing hepatitis E virus infection. The present invention further relates to the application of the monoclonal antibody or the active fragment or the conservative variant for preparing medicines for diagnosing, preventing and/or treating hepatitis E virus infection. The present invention also comprises a medical composition used for treating hepatitis E virus infection and a method for preventing and/or treating hepatitis E virus infection. The present invention also relates to a recombinant expression carrier containing the ribonucleic acid molecule in the present invention, a host cell converted by the recombinant.
Participants in this study arm will not have access to the mobile messaging application during the course of the study. After the Month 9 follow up assessment participants in this study arm will be offered access to HealthMindr.
Participants will be scanned using anatomical magnetic resonance imaging (MRI) and PET. All participants will receive two PET scans, 4 weeks apart. CUD participants will be asked to abstain from cannabis for the 4 week period.
PURPOSE: Central nervous system involvement by Brucella species is the most morbid form of brucellosis disease. Studies on neurobrucellosis are scarce and limited to case reports and series. Brucella is unable to infect or harm neurons without the assistance of monocytes. This raises the question of whether ceftriaxone-based regimens are effective.
METHODS: The primary aim of this study was to identify, evaluate, and summarize the findings of all relevant individual studies in the past 30 years to help better understand the disease. To achieve this, a broad systematic search was undertaken to identify all relevant records. Epidemiological and clinical features of the disease were assessed by the pooled analysis of descriptive studies. Through a meta-analysis, the treatment period duration was compared between the ceftriaxone-based and oral regimens using Standardized mean differences to measure effect size.
RESULTS: 448 patients were included in the Meta-analyses from 5 studies. A moderate positive effect was found for ceftriaxone-based regimens over oral treatments, and there was a significant difference between these two groups (SMD 0.428, 95% CI -0.63 to -0.22, I 2 = 37.64). Neurobrucellosis has a different clinical picture in pediatric patients. The disease is less chronic in children. Fever, nausea and vomiting, fatigue, and abdominal pain were significantly more prevalent symptoms in children, and Convulsions, ascites, sensorineural hearing loss, and papilledema were significantly more prevalent signs in children than adults.
CONCLUSION: It is recommended to initiate the treatment of neurobrucellosis with IV ceftriaxone therapy in combination with oral therapy.
Gastrointestinal (GI) cancers impose a substantial global health burden, highlighting the necessity for deeper understanding of their intricate pathogenesis and treatment strategies. This review explores the interplay between intratumoral microbiota, tumor metabolism, and major types of GI cancers (including esophageal, gastric, liver, pancreatic, and colorectal cancers), summarizing recent studies and elucidating their clinical implications and future directions. Recent research revealed altered microbial signatures within GI tumors, impacting tumor progression, immune responses, and treatment outcomes. Dysbiosis-induced alterations in tumor metabolism, including glycolysis, fatty acid metabolism, and amino acid metabolism, play critical roles in cancer progression and therapeutic resistance. The integration of molecular mechanisms and potential biomarkers into this understanding further enhances the prognostic significance of intratumoral microbiota composition and therapeutic opportunities targeting microbiota-mediated tumor metabolism. Despite advancements, challenges remain in understanding the dynamic interactions within the tumor microenvironment (TME). Future research directions, including advanced omics technologies and prospective clinical studies, offer promising avenues for precision oncology and personalized treatment interventions in GI cancer. Overall, integrating microbiota-based approaches and molecular biomarkers into GI cancer management holds promise for improving patient outcomes and survival.
FIELD: medicine; cosmetics. SUBSTANCE: method involves destroying skin water barrier to increase transepidural moisture loss during prolonged time (weeks or months), applying mechanical and dissolving action like taking-off with ribbon or washing with acetone. Cosmetic creams and gels with active ingredients like lactic acid as primary water-soluble agent for destroying the barrier are used in treatment. Retinoid like sodium palmitate of vitamin A is administered as lipid-soluble agent for destroying the barrier. Some known cerebroside for inhibiting barrier restoration is used. Creams and gels are useable for a long time to provide continuous mode of supported barrier destruction process. EFFECT: improved state and structure of sensitive face skin zones; repaired young skin appearance; no adverse side effects. 25 cl, 4 tbl
Background and Objectives: Skull base reconstruction is a crucial step during transsphenoidal surgery. Sphenoid mucosa is a mucosal membrane located in the sphenoid sinus. Preservation and lateral shifting of sphenoid mucosa as sphenoid mucosal flap (SMF) during the transsphenoidal exposure of the sella may be important for later closure. This is the first systematic review to evaluate the utility of sphenoid mucosal flap for sellar reconstruction after transsphenoidal surgery. Materials and Methods: A systematic literature search was performed in January 2023: Cochrane, EMBASE, PubMed, Scopus, and Web of Science. The following keywords and their combinations were used: "sphenoid mucosa", "sphenoid sinus mucosa", "sphenoid mucosal flap", "sphenoid sinus mucosal flap". From a total number of 749 records, 10 articles involving 1671 patients were included in our systematic review. Results: Sphenoid sinus mucosa used to be applied for sellar reconstruction as either a vascularized pedicled flap or as a free flap. Three different types of mucosal flaps, an intersinus septal flap, a superiorly based flap and an inferiorly based flap, were described in the literature. Total SMF covering compared to partial or no SMF covering in sellar floor reconstruction resulted in fewer postoperative CSF leaks (p = 0.008) and a shorter duration of the postoperative lumbar drain (p = 0.003), if applied. Total or partial SMF resulted in fewer local complications (p = 0.012), such as fat graft necrosis, bone graft necrosis, sinusitis or fungal infection, in contrast to no SMF implementation. Conclusions: SMF seems to be an effective technique for skull base reconstruction after transsphenoidal surgery, as it can reduce the usage of avascular grafts such as fat along with the incidence of local complications, such as fat graft necrosis, bone graft necrosis, sinusitis and fungal infection, or it may improve the sinonasal quality of life by maintaining favorable wound healing through vascular flap and promote the normalization of the sphenoid sinus posterior wall. Further clinical studies evaluating sphenoid mucosal flap preservation and application in combination with other techniques, particularly for higher-grade CSF leaks, are required.
BACKGROUND AND OBJECTIVE: Nodal metastases in the central compartment are frequent in papillary thyroid cancer (PTC). However, they are mostly micrometastases with no impact on survival and their relevance on the risk of locoregional relapse is controversial. There is no consensus regarding optimal management of the central neck in patients with PTC cN0. In our center, we do not perform prophylactic central neck dissection (pCND). The objective of this study is to review our long-term results and compare them with the most recent literature.
PATIENTS AND METHODS: Retrospective review of patients with PTC who underwent total thyroidectomy (TT) without CND between 2005 and 2017. Primary result was disease-free survival in the neck (DFS).
RESULTS: 321 patients were identified, mostly T1-T2 tumors (94.1%). Median follow-up was 90 months. DFS in the central compartment was excellent (96.1% at 10 year's follow-up). 19 patients had cervical recurrence, of which 15 underwent salvage surgery. On their last visit, including salvage surgery when appropriate, 77% of patients had excellent response, 18.7% had indeterminate response, 3.1% had biochemically incomplete response and 1.2% had morphologically incomplete response. Recurrent laryngeal nerve (RLN) paralysis after TT was transient in 4.7% of patients and permanent in 0.9% of patients. There were no RLN paralysis after salvage surgery. Permanent hypoparathyroidism occurred in 3.4% of patients. Only one patient had hypoparathyroidism after salvage surgery and it was permanent.
CONCLUSIONS: Based on long-term results and low rate of complications associated with salvage surgery in our experience, we consider routine pCND is not justified.
KDOQI clinical practice guideline for nutrition in chronic kidney disease (CKD) uses a low-protein diet to reduce renal impairment and delay progression. The current research hotspot is dietary intervention. Time-restricted feeding was used to intervene in the progression of CKD. It restrict the time of eating but not the eaten calories, which have a higher compliance and safety. Studies have shown that intermittent fasting in obese patients with CKD is not only reduce body weight, but also improves glycolipid metabolism, reduces proteinuria and delays the progression of kidney disease. Intermittent fasting is currently a scientific research hotspot, and there are few international studies on the implementation of intermittent fasting to delay the deterioration of renal function in obese CKD patients, and lack of data on Chinese patients, which has great research potential. Based on the above background, this study was conducted as an pilot clinical trial to explore the effects of intermittent fasting on obese patients with CKD and to observe its effectiveness, safety and compliance.
For the induction phase: Seribantumab 3,000 mg IV weekly for 12 weeks then Maintenance Phase: Seribantumab 3,000 mg IV infusion once every 2 weeks, initiating approximately 14 days after completion of induction phase. Dose or schedule may be adjusted at the discretion of the treating physician.
A system and method for providing in real-time a health care plan of a target user, the method comprising: receiving, at an input unit [102], an input data associated with the target user and generating, by a processing unit [104], an analysed input data. Further, determining via a health assessment engine, a health status, and determining, one or more chronic conditions associated with the target user. Furthermore, identifying via a care indicator identification engine, one or more care indicators. Now, determining by the processing unit [104], a set of tracking parameters and determining, a set of treatment goal values. Now, automatically generating a target care plan and receiving, a first positive validation associated with the target care plan. Next, automatically allocating, the target care plan and generating, a health wellness meter. Further, providing in real-time by the processing unit [104], the health care plan of the target user.
Age-related macular degeneration (AMD) represents the most common cause of blindness in patients over the age of 60. Most vision loss in this disease results from sequelae of choroidal neovascular membrane (CNVM) formation. CNVM is usually composed of well-formed neovascularization and occult (less well-formed) neovascularization. While clinical trials have shown that some patients, mostly those with well-formed CNVM, may benefit from laser photocoagulation or photodynamic therapy, at present there is no treatment for patients who have combined CNVM lesions (both well-formed and occult) whose area of occult neovascularization is greater than 50% or who have other presentation of CNVM such as pigment-epithelial detachment or neovascular fibrosis.

Retinal histopathology of patients with choroidal neovascularization has revealed that areas of CNVM are usually fed by a few smaller choroidal feeder vessels originating from the choroid or choriocapillaris. Therefore, it has been hypothesized that closure of these feeder vessels would infarct the large CNVM complex. Until recently, identification of these feeder vessels has been difficult but new high speed indocyanine imaging of the choroid (Phi-motion) indocyanine green angiography (ICG) has allowed for more precise detection of these vessels. We will test this hypothesis by utilizing Phi-motion ICG to identify choroidal feeder vessels in patients with CNVM not amenable to approved treatments. If feeder vessels are identified, then pulse-diode laser photocoagulation will be used to attempt closure of these vessels. The study is designed to provide information on the feasibility of standardizing this procedure and estimating its potential efficacy. The primary outcome will be a greater than 50% reduction in the area of leakage from the neovascular component as determined by fluorescein angiogram. Secondary outcomes will include a complete resolution of leakage measured by fluorescein angiography, the number of repetitive laser treatments undergone, the number of patients eligible by fluorescein angiogram but without identifiable feeder vessels, and the number of patients with vision loss, from baseline, of 15 letters or more, 30 letters or more, or are reduced to less than 5 letters read. All adverse events regardless of severity or relatedness to the therapy will be collected and summarized. Assessment of all outcomes will be made at 6 weeks, 3, 6, 12, 18, and 24 months post laser treatment, and 24 months after enrollment. This study will give investigators some insight into this technology and the feasibility of this treatment in patients with various forms of neovascular AMD. In addition, the results of the study will provide the foundation for larger studies of this therapy.
An automated apparatus for the prevention and treatment of the Colony Collapse Disease (CCD) through the administration of nutrients and therapeutic to bee colonies to be treated comprises a box-like container (10) of a material resistant to atmospheric agents which accommodates in its interior at least a first reservoir (9) being liquid-tight fitted with a stirrer (12) and accessible from the outside through a first nozzle (4), an atomizing device (15) of a liquid solution or suspension of nourishment contained in the tank, means for the delivery (2, 1) of the liquid solution or suspension atomized into micrometric drops outside the apparatus, and a control unit (7) programmed for timing the delivery of the solution or suspension to the outside, for the determination of the amount of solution or suspension delivered and for emitting alarm signals in case of malfunctions of the apparatus or reduction of the solution or suspension in a liquid contained in the reservoir (9) below a predetermined level. The apparatus is powered by direct current with the energy supplied by a solar panel (5) located outside of the container and electrically connected to the control unit (7). Further disclosed is a liquid solution or suspension of nutrients that can be delivered in a spray form through the above deceived automated apparatus for the prevention and treatment of the Colony Collapse Disease (CCD). The solution or suspension comprises in a single aqueous solution or suspension of a) tonics and nutritious ingredients, mainly consisting of: milk powder and/or yeasts, sugars and lower organic acids; b) natural antioxidants and antiseptics contained in the extracts of one or more aromatic or medicinal plants selected from: Crocus sativus, Pelargonium graveolens, Monarda citriodora, Myristica fragrans, Origanum vulgare and Origanum majorana; and c) substances medicinal to bees, selected from thymol, oxalic acid, extracts of Thymus vulgaris, extracts of Aloe arborescens, extracts of Beta vulgaris cv. altissima and mixtures of two or more of the same. Also disclosed is a method for the prevention and treatment of the Colony Collapse Disease (CCD) through the administration of nutrients and therapeutic to bee colonies to be treated, consisting in using the above described automated apparatus deliver in a spray form, the above described solution or suspension.
Participants allocated to the waiting-list control arm will receive a link via email to educational materials related to COVID produced by King's College London for an online event and will be provided with the self-management booklet after completing the T2 assessment and qualitative interview. The topics covered in the online event are the same as the ones included in the self-management booklet, without structured guidance and behaviour change techniques to facilitate behaviour change.